Others have shown, however, that either pharmacological inhibition or ATG5 knockdown was insufficient to re-sensitize vemurafenib-resistant melanoma cells to this BRAFi, although higher activity of autophagy was assessed in resistant cells compared with drug-naïve counterparts [112]. Here, ATG5 is linked to melanoma.